chrisvoncsefalvay/vaers-outcomes huggingface dataset:
He described his reaction as something that was more or less like diarrhea, except that the only thing coming out was mucus.; He described his reaction as something that was more or less like diarrhea, except that the only thing coming out was mucus./he started having discharge through his rectum, like a mucous, no color to it; It did not stop until Sunday afternoon when his bowel movement returned to normal.; This is a spontaneous report from a contactable Consumer. An 81-years-old male patient reported himself that he received first dose of BNT162B2 (Pfizer-BioNTech COVID-19 Vaccine, formulation: Solution for injection, batch/lot number: EL9267) via an unspecified route of administration on 11Feb2021, Thursday at around 09:00 AM (at the age of 81-year-old) as DOSE 1, SINGLE for COVID-19 immunisation. The patient did not have medical history. The concomitant medications were not reported. The patient did not experience a reaction until Friday noon. On 12Feb2021, Friday around noon, the patient started having discharge through his rectum, like a mucous, no color to it. He described his reaction as something that was more or less like diarrhea, except that the only thing coming out was mucus. It did not stop until Sunday afternoon when his bowel movement returned to normal. On, Saturday morning the patient called a nurse through his insurance and she basically said if it does not don't go away call doctor Monday morning and made an appointment. On Saturday afternoon the patient had one little movement that was a little brown in color then it went right back to liquid, he could not stop it anytime gas came out or anything he couldn't stop it and that went on until noon Sunday and at noon on Sunday he had a movement, a little movement again which was brown and now it seems like it is back to normal. The patient did not know whether or not go see a doctor, he wanted to see if anyone has reported this before with the vaccine. He did not really know what he was trying it say but he wanted to try to find out if it was a reaction so he would know whether or not he can expect it the second time. At the time of this reported the discharge had resolved. The outcome of the events was recovered on an unspecified date in Feb2021.  Follow-up attempts were completed. No further information was expected.
Sx. localized reaction, 3 in. diameter; red, swollen area on upper arm. No treatment required.
STY IN RIGHT EYE; LITTLE LIQUID IN THE EAR; CHILLS; HEADACHE; DID NOT FEEL GOOD; ARM PAIN; SWELLING OF THE NECK; SWELLING OF THE LEFT SHOULDER; ENLARGED LYMPH NODES ON THE LEFT SIDE; NECK PAIN; TENDON TIGHTNESS; POPPING NOISE WHEN SWALLOWING; SUSPECTED COVID-19; SINUS ISSUE; This spontaneous report received from a patient concerned a 57 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included chronic hives, allergic to sulfa medications (welts all over the body), non-smoker, allergy to percocet (increased heart rate), latex allergy (skin burns), and sleep disorder. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, and expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 15:30 for prophylactic vaccination. Concomitant medications included cetirizine hydrochloride for chronic hives, and diphenhydramine hydrochloride for sleep disturbance.  On APR-2021, the subject experienced popping noise when swallowing. On APR-2021, the subject experienced suspected covid-19. On APR-2021, the subject experienced sinus issue. On 10-APR-2021, the subject experienced swelling of the neck. On 10-APR-2021, the subject experienced swelling of the left shoulder. On 10-APR-2021, the subject experienced enlarged lymph nodes on the left side. On 10-APR-2021, the subject experienced neck pain. On 10-APR-2021, the subject experienced tendon tightness. On 10-APR-2021, the subject experienced did not feel good. On 10-APR-2021, the subject experienced arm pain. On 10-APR-2021, the subject experienced headache. On 11-APR-2021, the subject experienced chills. On 15-APR-2021, Laboratory data included: COVID-19 virus test negative (NR: not provided) Negative. On 21-APR-2021, the subject experienced sty in right eye. On 21-APR-2021, the subject experienced little liquid in the ear. Laboratory data included: COVID-19 virus test negative (NR: not provided) Negative, and X-ray of nasal sinuses (NR: not provided) Normal sinuses. Treatment medications (dates unspecified) included: dextromethorphan hydrobromide/doxylamine succinate/ephedrine sulfate/ethanol/paracetamol, paracetamol, guaifenesin/pseudoephedrine hydrochloride, naproxen sodium, fluticasone propionate, dextromethorphan hydrobromide/guaifenesin/paracetamol/pseudoephedrine hydrochloride, and cefalexin. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from swelling of the neck, swelling of the left shoulder, enlarged lymph nodes on the left side, neck pain, tendon tightness, and arm pain on 13-APR-2021, and chills on 12-APR-2021, was recovering from sty in right eye, had not recovered from headache, and the outcome of popping noise when swallowing, suspected covid-19, did not feel good, sinus issue and little liquid in the ear was not reported. This report was non-serious.
second was 6/24/2011, she never got additional doses; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 71-year-old female patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (received 1st dose on 16th June 2011) and Twinrix (received 2nd dose on 24th June 2011).   On an unknown date, the patient received the 3rd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 21-MAY-2022 Reporter's Comments: The pharmacist reported that they had a patient who was given the accelerated dosing of Twinrix vaccine. The patient never got additional doses. The patient would be traveling and wanted to finish the series, but reporter were not sure where reporter need to start her on that. No further details were provided on voicemail. The reporter consented to follow up. Additional supportive information: Till the time of reporting, the patient did not receive further doses of Twinrix, which led to incomplete course of vaccination.
Nurse's first attempt administering intradermal Jynneos vaccine in the patient's right forearm did not create a wheal. As per CDC's interim recommendations, a second attempt was made. Nurse explained the error and dose details to patient. Patient agreed to receive a repeated dose of Jynneos vaccine. Nurse's second attempt was successful in creating a wheal 2 inches away from initial site. Patient was observed for 15 minutes post vaccination. No adverse reactions noted.
Onset Am of 2/2/03. Migraine headache, sweating, upset stomach, pulse racing. The follow up states pt was seen at MD following 2 days.
Severe gastrointestinal upset. Vomiting and diarrhea; Severe gastrointestinal upset. Vomiting and diarrhea; Severe gastrointestinal upset. Vomiting and diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received her first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: En6207), via an unspecified route of administration in the left arm on 17Mar2021 at 13:30 (at the age of 26-years-old), as a single dose for COVID-19 immunisation. The patients medical history included anxiety and depression. The patient had allergies to medications menthol (MANUFACTURER UNKNOWN) and doxycycline (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included PROZAC and PRILOSEC for unknown indications within 2 weeks of vaccination from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 28Jan2021, the patient experienced severe gastrointestinal upset, vomiting and diarrhoea. The clinical outcome of the events severe gastrointestinal upset, vomiting and diarrhoea was recovering. No follow-up attempts are needed. No further information is expected.
Wrong dose given-0.5 ml given versus 0.25 ml (H1N1 vaccine).
Extreme fatigue, Joint Pain full body, muscle pain, rapid heart rate, chest discomfort onset within 2-3 hours.  Progressive joint pain and headache within 24 hours, chest discomfort in and around the heart.  Sought medical treatment after pain discomfort dis not alleviate within 3 days, on 3/1/21.  Dr. prescribed steroid injection for inflammation, ordered cbc (negative) with follow up.  Possible indications of possible Pericarditis.  Follow up within 24-48 hours.  Joint pain has lessened from total body to being located in wrists, knees, ankles, toes.  Pressure/discomfort around heart/chest has lessened but not been eliminated.  Awaiting possible ECG/EKG
pt nl @ birth, doing well @ 4mo visit;pt recv vax & 1hr later fever 103, rising to 107 w/in 1hr;pt lethargic, vomit, fussy w/shrill cry never returned to nl;w/in 1wk devel infantile spasms, & develop delay w/loss of milestones;
Information has been received from a pharmacist, concerning unspecified child patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided. On an unknown date, the patient was vaccinated with a dose of VARIVAX (dose, frequency, route of administration, lot number and expiration date were not provided) for prophylaxis. On an unknown date, the patient was diagnosed with chicken pox. The outcome of chicken pox was unknown. The causal relationship between the adverse event and the therapy was not assessed. This is one of two report received from the same reporter. Sender's Comments: US-009507513-1712USA000896.
Patient began feeling nauseous and dizzy shortly after vaccine. Symptoms resolved after about 15 minutes
Patient had first JYNNEOS vaccination administered in clinic 8/9/2022, no immediate adverse reaction. Patient called clinic 8/12/2022 stating his left arm around vaccination site was extremely swollen "tennis ball sized" and painful- patient had appointment scheduled with PCP at local clinic that day and was evaluated- at first believed to have abscess at site but with further evaluation (including pictures from day before) patient was told the swelling had reduced and to take OTC NSAIDs and swelling should continue to decrease. Patient called clinic again 8/16/2022 stating "blisters" had appeared on his left forearm and right calf "not touching but clustered" Described the rash as both appearing "syphilis like" and "ringworm".  The rash started 8/15/2022 but the swelling in arm had decreased at this time. Patient instructed to follow-up with urgent care for further evaluation. Called patient 8/18/2022- swelling and rash have decreased, patient did not follow-up with urgent care but again instructed to follow-up.
Severe, persistent headache following the second dose of the vaccine, beginning approximately 22 hours after the administration of the vaccine and continuing, so far, for three days.
This spontaneous report was received from a pharmacist via company representative concerning a 65 year old female patient. Concomitant medication, pertinent medical history and drug reactions/allergies were reported as unknown. In January 2016 (reported as "about 6 months ago), the patient was vaccinated with a dose of ZOSTAVAX (lot number L046900) (dose, route, and expiration date reported as unknown). On an unknown date in 2016, the patient experienced a "rash the size of a baseball which was raised and painful" at the site of injection. The pharmacist reported that the patient did apply ice to the injection site and recovered on an unspecified date. The causality between the events and ZOSTAVAX was unknown. This is one of two cases from the same reporter. Additional information has been requested.
Significant joint pain; fatigue; left arm pain. -  Joint pain lasted 3 weeks from 12/27/2021 - 1/19/2021; Called Dr.  - telemed visit - 1/18/2021. I  had not recovered from the adverse symptoms of first dose before getting second dose. I had the second dose on  January 19, 2021 - had joint pain but I did so much easier than this first dose.
Eyes swallowed burning watery redness couldn?t see my sight. Eyes were cloudy with white spots that I couldn?t comprehend my daily life. Had a headache and sinuses as well
Information has been received from a physician concerning an adult female who on 10/22/03 was vaccinated with the second dose of pneumococcal 23v polysaccharide vaccine (lot # 647654/0865N). P1: six years ago. Subsequently the patient developed significant local and systemic (fever and joint pain) reactions. The physician indicated that the patient was not hospitalized, but she was treated with ceftriaxone sodium. No additional information was provided. Unspecified medical attention was sought. There was no product quality complaint. Follow up information from the physician indicated that he was only covering the office for 48 hours and he believes both were significant local reactions which did not require further treatment. Upon internal review, the significant local and systemic (fever and joint pains) reactions were considered to be other important medical events (OMIC). The reporter also indicated that one other patient was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot # 647654/0865N) and developed a similar reaction. Additional information has been requested.
Information had been received on 14-MAR-2017 from a nurse who reported that a 45 year old male patient received an expired dose of VAQTA (lot# L031196, expiration 05-FEB-2017) 50/1.0 U/ml (route of administration not reported) on 14-MAR-2017. No adverse effects were reported in the patient. No other information is available. Additional information has been requested.
Tested positive for Covid-19 on 9/13/2021.  Covid-19 S/S cough, fever and dizziness
This spontaneous report as received from a pharmacist, refers to a 65 year old female patient with morphine and "opiod analogs" allergy. The patient had no pertinent medical history. On 16-SEP-2013 the patient was vaccinated with ZOSTAVAX (lot number was not reported) 0.65 ml, once subcutaneous. There were no concomitant medications. Pharmacist stated that on 16-SEP-2013, since was vaccinated with ZOSTAVAX, experienced redness around injection site that started "small at time of injection and has grown bigger each day to 'the size of a tennis ball'". Pharmacist stated patient returned to pharmacy the day of the report, to show pharmacist her arm. Pharmacist stated patient had not contacted physician and had not had any treatment. The outcome of redness around injection site was not reported. The relationship between ZOSTAVAX and the redness around injection site was not reported. No lab diagnostics were performed. Additional information has been requested.
She has had 4 Pfizer COVID Vaccines for COVID and she has had COVID Twice; She has had 4 Pfizer COVID Vaccines for COVID and she has had COVID Twice; She has had 4 Pfizer COVID Vaccines for COVID and she has had COVID Twice; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP), Program ID: (086396). The reporter is the patient.  An 85-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "GERD" (ongoing); "Thyroid" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: SUSPECTED COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), DISEASE RECURRENCE (medically significant), outcome "unknown" and all described as "She has had 4 Pfizer COVID Vaccines for COVID and she has had COVID Twice".  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.
from 7-14 days after the first shot, she developed a small rash (irritated rash) on her neck and arm which has since resolved and recently a cough like a cold.; from 7-14 days after the first shot, she developed a small rash (irritated rash) on her neck and arm which has since resolved and recently a cough like a cold.; from 7-14 days after the first shot, she developed a small rash (irritated rash) on her neck and arm which has since resolved and recently a cough like a cold.; This is spontaneous report from a contactable consumer (patient). A 65-years-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on Mar2021 as dose 1, single for covid-19 immunisation. The patient medical history included respiratory problems from an unknown date and unknown if ongoing. The patient concomitant medications were not reported. On unspecified date, the patient took first dose of Pfizer COVID vaccine about 3 weeks ago and had no problems afterwards but states anywhere from 7-14 days after the first shot, she developed a small rash (irritated rash) on her neck and arm which has since resolved and recently a cough like a cold. Patient states she applied antiitch topically to her rash. States she was due for her second shot today. States she read that if she experienced a rash then she shouldn't get the second shot. The outcome of events was unknown.  No follow-up attempts are completed; information about lot/batch number cannot be obtained.
Information has been received from a registered nurse concerning a 22 year old adult female with no known medical history and no known allergies who on 6/17/03 at 14:00 was vaccinated SC in the left upper arm with a first dose of varicella virus vaccine live (lot # 643588/0804M). There was no concomitant medication. There was no illness at the time of vaccination. There were no adverse events following prior vaccination. The patient presented today, 15 days after vaccination, on 7/2/03, (also reported as 7/3/03) with a single, red, hot, itchy, hard not at the injection site that was 5cm in diameter and a 99.1 F temperature. On 7/7/03, it was noted that the patient reported she had a temperature of 100.0, a headache and had broken out in chicken pox. On 7/7/03, it was observed that the patient had scattered pustules on the face, chest, axilla, and back in various stages of healing. It was also noted that the approximate number of pustules on her face was 8; axilla, 4 on each; back, 20; and chest, 6. She was not allowed to be in the work place. On 6/2/03, a varicella titer was negative. Medical attention was sought. Treatment included acetaminophen, ice or diphenhydramine HCl cream as needed. On 7/11/03, the patient was allowed to return to work, the spots were dry, scabbed and vanishing. It was noted that the patient recovered. No further information is expected.
pt recvd vax;2 wks p/ dose 1, exp tunnel vision & fainted;immed p/ dose 2,exp dyspnea,hives,dec blood sugar level & fainted; 4may94 pt fainted;
Dose given past expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose given past expiration date) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001J21-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Feb-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose given past expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose given past expiration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Refrigerator expiration date reported as 05-Feb-2022 as it was removed from freezer on 06-Jan-2022. No temperature excursion was reported during storage.  No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 11-Feb-2022: Non significant follow up received.
pain at injection site; This is a spontaneous report received from a contactable reporter(s) (Physician).  A 69 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 03Dec2021 (Lot number: FH8028) at the age of 69 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Depression" (ongoing). Concomitant medication(s) included: PRISTIQ taken for affective disorder (ongoing). Vaccination history included: Bnt162b2 (Dose: 1st, Date/Time: 16Feb2021, Site and Route of Injection: , Anatomical Site of Injection: Rt deltoid, Batch/Lot Number: EN6200), administration date: 16Feb2021, when the patient was 69 years old, for Covid-19 immunization, reaction(s): "Vaccination site pain"; Bnt162b2 (Dose: 2nd , Date/Time: 09Mar2021, Site and Route of Injection: , Anatomical Site of Injection: Lt deltoid, Batch/Lot Number: EN6204), administration date: 09Mar2021, when the patient was 69 years old, for COVID-19 Immunization. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 09Dec2021, outcome "recovering", described as "pain at injection site". Therapeutic measures were taken as a result of vaccination site pain.  Additional Information: The patient provide information to you regarding the reported adverse event(s) with the use of the product. The Pfizer product had a causal effect to the adverse event. Vaccination Facility Type: Unknown, list any other vaccinations within four weeks prior to the first administration date of the sus-pect. Relevant Tests were one. Specific Relevant Test for Thromboembolic events with Thrombocy-topenia were none Autopsy Information: N/A. On 09Dec2021, 6 days after her booster shot we had an office visit, where she Complained of pain at injection site that improved with Skelaxin.  No follow-up attempts are possible. No further information is expected.
Headache, Myalgia & Fever Narrative:  Fever, body ache, chills, fatigue, headache